Abstract
Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.
| Original language | English |
|---|---|
| Journal | European journal of Clinical and Medical Oncology |
| Volume | 2 |
| Issue number | 2 |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- Everolimus
- Grading system
- Pancreatic neuroendocrine tumor
- Sunitinib
- TNM
- WHO classification
ASJC Scopus subject areas
- Oncology
Cite this
Pancreatic neuroendocrine tumors : A focus on the current classification and molecular targeted therapy. / Squadroni, Michela; Formica, Vincenzo; di Meglio, Giovanni; Dealis, Cristina; Spada, Francesca; Lorizzo, Katia; Fazio, Nicola.
In: European journal of Clinical and Medical Oncology, Vol. 2, No. 2, 2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pancreatic neuroendocrine tumors
T2 - A focus on the current classification and molecular targeted therapy
AU - Squadroni, Michela
AU - Formica, Vincenzo
AU - di Meglio, Giovanni
AU - Dealis, Cristina
AU - Spada, Francesca
AU - Lorizzo, Katia
AU - Fazio, Nicola
PY - 2010
Y1 - 2010
N2 - Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.
AB - Although their incidence has been rising over the last decades, pancreatic neuroendocrine tumors (PNETs) are relatively uncommon, accounting for less than 5% of all primary pancreatic malignancies. They are classified based on morphological and biological characteristics. The World Health Organization (WHO) classification from 2000 subcategorizes gastroenteropancreatic neuroendocrine tumors into welldifferentiated tumors, well-differentiated carcinomas, and poorly differentiated carcinomas; the TNM staging system from 2006 considers three "G" groups based on the Ki-67 level and three "T" groups related to the size. Retrospective analyses confirmed the prognostic relevance of both WHO and TNM staging systems for PNETs. As for treatment, chemotherapy, somatostatin analogs, interferon, and peptide radioreceptor therapy can have a role in PNETs. Over the last decade several molecular targeted agents have been studied. Among them sunitinib and everolimus are in the most advanced phase of clinical investigation. This is a literature review, based on a Medline search for pancreatic neuroendocrine tumor and carcinoma, which will focus on the clinical importance of classifications and the advances of molecular targeted therapies in PNETs.
KW - Everolimus
KW - Grading system
KW - Pancreatic neuroendocrine tumor
KW - Sunitinib
KW - TNM
KW - WHO classification
UR - http://www.scopus.com/inward/record.url?scp=77956277391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956277391&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77956277391
VL - 2
JO - European journal of Clinical and Medical Oncology
JF - European journal of Clinical and Medical Oncology
SN - 1759-8958
IS - 2
ER -